Novo Nordisk's recent Q3 2025 earnings report reveals a robust demand for its weight-loss drug Wegovy, with U.S. sales up by 15% at constant exchange rates. This is significant as it highlights the drug's effectiveness and popularity, even amidst rising costs and pricing pressures that have led the company to adjust its full-year guidance. The continued success of Wegovy not only reflects consumer interest in effective weight management solutions but also underscores the growing market for obesity treatments.